Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

Michael Wang, MD, John M. Rossi, MS, Javier Munoz, MD, Andre H. Goy, MD, Frederick L. Locke, MD, Patrick M. Reagan, MD, Caron A. Jacobson, MD, Brian T. Hill, MD, Houston Holmes, Samantha Jaglowski, MD MPH, Weimin Peng, PhD, Lianqing Zheng, PhD, Xiang Fang, PhD, Allen Xue, PhD, Ioana Kloos, MD, Adrian Bot, MD PhD

Blood (2020) 136 (Supplement 1): 29.

https://doi.org/10.1182/blood-2020-136831

Published: 2020

Journal Articles

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

Sattva S Neelapu, MD, John M. Rossi, MS, Caron A. Jacobson, MD, Frederick L. Locke, MD, David B. Miklos, MD PhD, Patrick M Reagan, MD, Scott J Rodig, MD PhD, Lazaros J. Lekakis, MD, Ian W. Flinn, MD PhD, Lianqing Zheng, PhD, Francesca Milletti, PhD, Edmund Chang, PhD, Allen Xue, PhD, Vicki Plaks, PhD, Jenny J. Kim, MD MS, Adrian Bot, MD PhD

Blood (2019) 134 (Supplement_1): 203.

https://doi.org/10.1182/blood-2019-126218

Published: 2019

Journal Articles

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

Jennifer Brudno, MD, Steven Hartman, Norris Lam, BS, David F. Stroncek, John M. Rossi, MS, Yueh-wei Shen, Allen Xue, PhD, Adrian Bot, MD PhD, Jennifer A Kanakry, MD, Steven Z. Pavletic, MD, Lekha Mikkilineni, MD, Mark Roschewski, MD, Robert M. Dean, MD, Jeremy J. Rose, MS, Rashmika Patel, Brenna Hansen, Steve A. Rosenberg, Ronald E. Gress, MD, James N. Kochenderfer, MD

Blood (2018) 132 (Supplement 1): 697.

https://doi.org/10.1182/blood-2018-99-113731

Published: 2018

Journal Articles

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

Blood (2018) 132 (Supplement 1): 2967.

https://doi.org/10.1182/blood-2018-99-111368

Published: 2018

Journal Articles

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Bijal D. Shah, MD, Wendy Stock, MD, William G Wierda, MD PhD, Olalekan Oluwole, MBBS, MPH, Houston Holmes, MD FACP, Gary J. Schiller, MD FACP, Max S. Topp, MD, Marie José Kersten, MD PhD, Roch Houot, MD PhD, Nicolas Boissel, MD PhD, Michelle Mojadidi, MSc, Allen Xue, PhD, Armen Mardiros, PhD, Yizhou Jiang, PhD, Tong Shen, PhD, Jeff S. Aycock, Shanna Stout, Jeffrey S. Wiezorek, MD MS, Rajul Jain, MD

Blood (2017) 130 (Supplement 1): 888.

https://doi.org/10.1182/blood.V130.Suppl_1.888.888

Published: 2017

Journal Articles

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Frederick L. Locke, MD, Jason R. Westin, MD, David B. Miklos, MD PhD, Alex F. Herrara, MD, Caron A. Jacobson, MD, Jennifer Lee, John M. Rossi, MS, Adrian Bot, MD PhD, Allen Xue, PhD, Lynn Navale, MS, Jeff S. Aycock, Jeffrey S. Wiezorek, MD MS, Zachary J. Roberts, MD PhD

Blood (2017) 130 (Supplement 1): 2826.

https://doi.org/10.1182/blood.V130.Suppl_1.2826.2826

Published: 2017

NARROW

Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial

CD19-Loss with Preservation of Other B Cell Lineage Features in Patients with Large B Cell Lymphoma Who Relapsed Post-Axi-Cel

Low Levels of Neurologic Toxicity with Retained Anti-Lymphoma Activity in a Phase I Clinical Trial of T Cells Expressing a Novel Anti-CD19 CAR

2-Year Follow-up and High-Risk Subset Analysis of Zuma-1, the Pivotal Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Refractory Large B Cell Lymphoma

Phase 1 Results of ZUMA-3: KTE-C19, an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, in Adult Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia (R/R ALL)

Phase 1 Results from ZUMA-6: Axicabtagene Ciloleucel (axi-cel; KTE-C19) in Combination with Atezolizumab for the Treatment of Patients with Refractory Diffuse Large B Cell Lymphoma (DLBCL)

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only